Descriptor analysis of estrogen receptor β-selective ligands using 2-phenylquinoline, tetrahydrofluorenone and 3-hydroxy 6H-benzo[c]chromen-6-one scaffolds

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 6, 2011, Pages 831-842

  Balaji, ^a   Muthiah, Ramanathan ^a   Sabarinath, ^b   Ramamurthy, ^b   Chandrasekharan, ^a  

^a PSG COLLEGE OF PHARMACY   (India)

^b PSG COLLEGE OF TECHNOLOGY   (India)

Author keywords

3 hydroxy 6H benzo c chromen 6 one; Anti cancer; ER and receptors; Estrogen; Phenylquinoline; Tetrahydrofluorenone

Indexed keywords

2 PHENYLQUINOLINE DERIVATIVE; 3 HYDROXY 6H BENZO[C]CHROMEN 6 ONE DERIVATIVE; ESTROGEN RECEPTOR BETA; FLUORENONE DERIVATIVE; HALOGEN; TETRAHYDROFLUORENONE; UNCLASSIFIED DRUG;

ARTICLE; ATOM; BINDING AFFINITY; LIPOPHILICITY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BENZOPYRANS; ESTROGEN RECEPTOR BETA; FLUORENES; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES;

EID: 81355138289     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.566219     Document Type: Article

References (36)

1. Katzenellenbogen BS. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol Reprod 1996;54:287-293. (Pubitemid 26031396)
2. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930. (Pubitemid 26190778)
3. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53. (Pubitemid 26268330)
4. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997;82:4258-4265. (Pubitemid 27525550)
5. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol 1997;11:353-365. (Pubitemid 27106331)
6. Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD et al. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem 2004;47:5021-5040. (Pubitemid 39314900)
7. Imamov O, Shim GJ, Warner M, Gustafsson JA. Estrogen receptor beta in health and disease. Biol Reprod 2005;73:866-871. (Pubitemid 41507488)
8. Koehler KF, Helguero LA, Haldoseacute;n LA, Warner M, Gustafsson JA. Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 2005;26:465-478. (Pubitemid 40691301)
9. Vedani A, Smiesko M, Spreafico M, Peristera O, Dobler M. VirtualToxLab - in silico prediction of the toxic (endocrinedisrupting) potential of drugs, chemicals and natural products. Two years and 2,000 compounds of experience: a progress report. Altex 2009;26:167-176.
10. Cao Q, Garib V, Yu Q, Connell DW, Campitelli M. Quantitative structure-property relationships (QSPR) for steroidal compounds of environmental importance. Chemosphere 2009;76:453-459.
11. Roncaglioni A, Piclin N, Pintore M, Benfenati E. Binary classification models for endocrine disrupter effects mediated through the estrogen receptor. SAR QSAR Environ Res 2008;19:697-733.
12. Li H, Ung CY, Yap CW, Xue Y, Li ZR, Chen YZ. Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. J Mol Graph Model 2006;25:313-323. (Pubitemid 44740069)
13. Boriani E, Spreafico M, Benfenati E, Novic M. Structural features of diverse ligands influencing binding affinities to estrogen alpha and estrogen beta receptors. Part I: Molecular descriptors calculated from minimal energy conformation of isolated ligands. Mol Divers 2007;11:153-169.
14. Spreafico M, Boriani E, Benfenati E, Novic M. Structural features of diverse ligands influencing binding affinities to estrogen alpha and estrogen beta receptors. Part II. Molecular descriptors calculated from conformation of the ligands in the complex resulting from previous docking study. Mol Divers 2007;11:171-181.
15. Hillisch A, Peters O, Kosemund D, Müller G, Walter A, Schneider B et al. Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol Endocrinol 2004;18:1599-1609. (Pubitemid 38859569)
16. Vu AT, Cohn ST, Manas ES, Harris HA, Mewshaw RE. ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett 2005;15:4520-4525. (Pubitemid 41253886)
17. Wilkening RR, Ratcliffe RW, Tynebor EC, Wildonger KJ, Fried AK, Hammond ML et al. The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands. Bioorg Med Chem Lett 2006;16:3489-3494. (Pubitemid 43792529)
18. Sun W, Cama LD, Birzin ET, Warrier S, Locco L, Mosley R et al. 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett 2006;16:1468-1472. (Pubitemid 43197502)
19. Trossini GH, Guido RV, Oliva G, Ferreira EI, Andricopulo AD. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies. J Mol Graph Model 2009;28:3-11.
20. Leonard JT, Roy K. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Eur J Med Chem 2008;43:81-92.
21. Hu QN, Liang YZ, Yin H, Peng XL, Fang KT. Structural interpretation of the topological index. 2. The molecular connectivity index, the kappa index, and the atom-type E-state index. J Chem Inf Comput Sci 2004;44:1193-1201.
22. Ullrich JW, Unwalla RJ, Singhaus RR Jr, Harris HA, Mewshaw RE. Estrogen receptor beta ligands: design and synthesis of new 2-phenyl-isoindole-1,3- diones. Bioorg Med Chem Lett 2007;17:118-122. (Pubitemid 44959983)
23. Umamatheswari S, Balaji B, Ramanathan M, Kabilan S. Synthesis, antimicrobial evaluation and QSAR studies of novel piperidin- 4-yl-5-spiro-thiadiazoline derivatives. Bioorg Med Chem Lett 2010;20:6909-6914.
24. Hansch C, Verma RP. A QSAR study for the cytotoxic activities of taxoids against macrophage (MPhi)-like cells. Eur J Med Chem 2009;44:274-279.
25. Strike, version 1.8, Schrödinger, LLC, New York, NY, 2009.
26. Roy K. On some aspects of validation of predictive quantitative structure-activity relationship models. Expert Opin Drug Discov 2007;2:1567-1577. (Pubitemid 350285346)
27. LigPrep, version 2.3, Schrödinger, LLC, New York, NY, 2009.
28. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engström O et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. Embo J 1999;18:4608-4618. (Pubitemid 29415516)
29. Maestro, version 9.0, Schrödinger, LLC, New York, NY, 2009.
30. Prime, version 2.1, Schrödinger, LLC, New York, NY, 2009.
31. Glide, version 5.5, Schrödinger, LLC, New York, NY, 2009.
32. Pike AC. Lessons learnt from structural studies of the oestrogen receptor. Best Pract Res Clin Endocrinol Metab 2006;20:1-14. (Pubitemid 43328570)
33. Manas ES, Unwalla RJ, Xu ZB, Malamas MS, Miller CP, Harris HA et al. Structure-based design of estrogen receptor-beta selective ligands. J Am Chem Soc 2004;126:15106-15119. (Pubitemid 39557270)
34. Fang H, Tong W, Shi LM, Blair R, Perkins R, Branham W et al. Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem Res Toxicol 2001;14:280-294. (Pubitemid 32238488)
35. Chang HJ, Kim HJ, Chun HS. Quantitative structure-activity relationship (QSAR) for neuroprotective activity of terpenoids. Life Sci 2007;80:835-841. (Pubitemid 46164811)
36. Hansch C, Verma RP, Kurup A, Mekapati SB. The role of QSAR in dopamine interactions. Bioorg Med Chem Lett 2005;15:2149-2157. (Pubitemid 40445484)